GE MEDICAL SYSTEMS

The FDA approved GE HealthCare’s Flyrcado, a PET MPI agent for diagnosing CAD, offering improved accuracy over SPECT MPI. Flyrcado, with a 109-minute half-life, demonstrated superior efficacy in the AURORA trial compared to SPECT and was validated against coronary angiography. Expected to launch in the U.S. early next year, it aims to address limited access to PET tracers and improve CAD diagnosis.

GE HealthCare's Flyrcado (flurpiridaz F 18) injection, an FDA-approved PET MPI agent for CAD detection, aims to improve access to PET MPI, especially for challenging-to-image patients. Flyrcado, developed in collaboration with Lantheus, is expected to be available in initial US markets in early 2025.

The U.S. AI in oncology market, valued at USD 888.31 million in 2023, is projected to reach USD 7,710.88 million by 2032 with a CAGR of 27.1%. Breast cancer leads in market share due to innovative solutions aiding diagnosis and treatment. Key players include Azra AI, ConcertAI, GE HealthCare, and IBM. AI technologies transform cancer care, from early detection to personalized medicine, driving market growth.

The Medical Image Analytics Market is projected to reach USD 577.02 billion by 2032, driven by advancements in healthcare technology, AI integration, and rising demand for precise diagnostic tools. Key players include Siemens Healthineers, GE Healthcare, and IBM Watson Health, with significant growth expected in North America, Europe, and Asia Pacific.

FDA approves flurpiridaz F 18 (Flyrcado) for myocardial ischemia and infarction evaluation in adults, with sensitivity 74-89% and specificity 53-70% for CAD detection. Common adverse events include dyspnea and headache, with risks of serious events like myocardial infarction and arrhythmia.

The Medical Nanotechnology Market is projected to reach $334.7 billion by 2032, driven by advancements in diagnostics, drug delivery, and tissue engineering. Key players include Siemens Healthineers, GE Healthcare, and Johnson & Johnson. Market growth is fueled by personalized medicine, chronic disease treatment, and increased R&D investments.

FDA approves Flyrcado™, a PET MPI agent for CAD detection with higher efficacy than SPECT, longer half-life, and potential to expand PET imaging access. Flyrcado shows advantages in diagnosing CAD in obese patients and reduces radiation exposure.

FDA approves GE HealthCare's flurpiridaz F-18, a PET myocardial perfusion imaging radiotracer for CAD detection, marketed as Flyrcado. It offers higher diagnostic efficacy than SPECT MPI, with a 109-minute half-life, enabling exercise stress testing and rescanning during the same session. Flurpiridaz's approval is expected to expand PET adoption, addressing access and cost barriers, and is seen as a game changer in noninvasive CAD diagnosis.

GE HealthCare's Flyrcado, a radiotracer for coronary heart disease diagnosis, received FDA approval. It can be manufactured offsite and has a 109-minute half-life, enabling exercise stress testing with cardiac PET imaging. It will be available in the U.S. early next year.